Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13:1387–97. Available from: https://pubmed.ncbi.nlm.nih.gov/29209143/. Cited 6 Oct 2021.

CAS  PubMed  Article  PubMed Central  Google Scholar 

WHO. Breast cancer. Geneva: WHO; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. Cited 6 Oct 2021.

Google Scholar 

Danforth DN. Risk assessment for sporadic breast cancer: the need for a molecular profile. Clin Surg. 2018;3:1–4. Available from: http://clinicsinsurgery.com/.

Google Scholar 

Larsen MJ, Thomassen M, Gerdes AM, Kruse TA. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer Basic Clin Res. 2014;8:145–55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213954/. Cited 6 Oct 2021.

Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod Pathol. 2005;18(10):1305–20. Available from: https://www.nature.com/articles/3800453. Cited 6 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4(8):1066–72. Available from: https://pubmed.ncbi.nlm.nih.gov/29801090/. Cited 6 Oct 2021.

PubMed  Article  PubMed Central  Google Scholar 

Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: Setting paradigms in personalized cancer care and prevention. Science. 2014;343:1466–70. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074902/. NIH Public Access. Cited 6Oct 2021.

Zimmerman B. In: Jackson MS, editor. Understanding breast cancer genetics: University Press of Mississippi; 2004.

Google Scholar 

NCCN. National Comprehensive Cancer Network. Familial/Genetic, High-Risk Assessment, Breast, Ovarian and Pancreatic (Version 2.2021): National Comprehensive Cancer Network; 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_boppdf. Accessed 30 Jan 2021. Cited 31 Jan 2021.

Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7:937–48. Available from: https://pubmed.ncbi.nlm.nih.gov/18034184/. Cited Oct 6 2021.

CAS  PubMed  Article  Google Scholar 

De Juan JI, García Casado Z, Palanca Suela S, Esteban Cardeñosa E, López Guerrero JA, Segura Huerta Á, et al. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence. Fam Cancer. 2013;12(4):767–77. Available from: https://pubmed.ncbi.nlm.nih.gov/23479189/. Cited 6 Oct 2021.

Article  CAS  Google Scholar 

Ibáñez EE. Impact of the genetic study of BRCA 1 and BRCA 2 in the therapeutic decision in triple negative diagnosed breast cancer patients receiving neoadjuvant chemotherapy. 2015. Available from: https://zaguan.unizar.es/record/10321/files/TAZ-TFM-2013-144.pdf.

Google Scholar 

Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L. Comprehensive BRCA1 and BRCA2 mutational profile in lithuania. Cancer Genet. 2014;207(5):195–205. Available from: https://pubmed.ncbi.nlm.nih.gov/25066507/. Cited 6 Oct 2021.

PubMed  Article  CAS  Google Scholar 

Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, et al. Spectrum and characterisation of BRCA1 and BRCA2deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer. 2008;8(1):1–11. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-8-140. Cited 6 Oct 2021.

Article  CAS  Google Scholar 

Stegel V, Krajc M, Žgajnar J, Teugels E, De Grève J, Hočevar M, et al. The occurrence of germline BRCA1 and BRCA2sequence alterations in Slovenian population. BMC Med Genet. 2011;12(1):1–11. Available from: https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-12-9. Cited Oct 6 2021.

Article  CAS  Google Scholar 

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. J Am Med Assoc. 2006;295(12):1379–88. Available from: https://pubmed.ncbi.nlm.nih.gov/16551709/. Cited 6 Oct 2021.

CAS  Article  Google Scholar 

Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2 : analysis of 10,000 individuals. J Clin Oncol. 2002;20(6):1480–90. Available from: https://pubmed.ncbi.nlm.nih.gov/11896095/. Cited 6 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, et al. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. J Hum Genet. 2017;63(4):447–457.M.

PubMed  Article  PubMed Central  Google Scholar 

Kim DH, Chae H, Jo I, Yoo J, Lee H, Jang W, et al. Identification of large genomic rearrangement of BRCA1/2 in high risk patients in Korea. BMC Med Genet. 2017;18(1):1–7. Available from: https://bmcmedgenet.biomedcentral.com/articles/10.1186/s12881-017-0398-3. Cited 6 Oct 2021.

CAS  Google Scholar 

Kang E, Seong MW, Park SK, Lee JW, Lee J, Kim LS, et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015;151(1):157–68. Available from: https://pubmed.ncbi.nlm.nih.gov/25863477/. Cited 6 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Liede A, Malik IA, Aziz Z, De los Rios P, Kwan E, Narod SA. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet. 2002;71(3):595–606. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC379195/. Cited 1 Oct 2021.

Rashid MU, Muhammad N, Naeemi H, Khan FA, Hassan M, Faisal S, et al. Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: Results from a large comprehensive study. Hered Cancer Clin Pract. 2019;17(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31528241/. Cited 6 Oct 2021.

Rashid MU, Muhammad N, Amin A, Loya A. Hamann U. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan. Breast Cancer Res Treat. 2017;161(2):191–201. Available from: https://pubmed.ncbi.nlm.nih.gov/27826754/. Cited 1 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, et al. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer. 2006;119(12):2832–9. Available from: https://pubmed.ncbi.nlm.nih.gov/16998791/. Cited 1 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Rashid MU, Gull S, Asghar K, Muhammad N, Amin A, Hamann U. Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Fam Cancer. 2012;11(2):307–11. Available from: https://link.springer.com/article/10.1007/s10689-012-9509-7. Cited 2021 Oct 6.

CAS  PubMed  Article  Google Scholar 

Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U. Prevalence of PALB2 germline mutations in early-onset and familial breast/ovarian cancer patients from Pakistan. Cancer Res Treat. 2019;51(3):992–1000. Available from: https://pubmed.ncbi.nlm.nih.gov/30309218/. Cited 6 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan. BMC Cancer. 2013;13. Available from: https://pubmed.ncbi.nlm.nih.gov/23806170/. Cited 1 Oct 2021.

Rashid MU, Muhammad N, Khan FA, Shehzad U, Naeemi H, Malkani N, et al. Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients. Hered Cancer Clin Pract. 2020;18(1):1–9. Available from: https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-020-00159-6. Cited 2021 Oct 6.

CAS  Article  Google Scholar 

Rashid M, Muhammad N, Faisal S, Amin A, Hamann U. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Res Treat. 2014;145(3):775–84. Available from: https://pubmed.ncbi.nlm.nih.gov/24800917/.

CAS  PubMed  Article  Google Scholar 

Catana A, Apostu AP, Antemie RG. Multi gene panel testing for hereditary breast cancer - Is it ready to be used? Med Pharm Rep. 2019;92(3):220–5. Available from: https://pubmed.ncbi.nlm.nih.gov/31460501/. Cited 6 Oct 2021.

PubMed  PubMed Central  Google Scholar 

LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, et al. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22(2):407–15. Available from: https://pubmed.ncbi.nlm.nih.gov/31406321/. Cited 6 Oct 2021.

CAS  PubMed  Article  Google Scholar 

Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440–51. Available from: https://pubmed.ncbi.nlm.nih.gov/33471974/. Cited 6 Oct 2021.

PubMed  Article  PubMed Central  Google Scholar 

Kwong A, Shin VY, Au CH, Law FBF, Ho DN, Ip BK, et al. Detection of germline mutation in hereditary breast and/or ovarian cancers by next-generation sequencing on a four-gene panel. J Mol Diagnostics. 2016;18(4):580–94. Available from: https://pubmed.ncbi.nlm.nih.gov/27157322/. Cited 6 Oct 2021.

CAS  Article  Google Scholar 

Kurian AW, Kingham KE, Ford JM. Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Curr Opin Obstet Gynecol. 2015;27:23–33. Available from: https://pubmed.ncbi.nlm.nih.gov/25502425/. Cited 6 Oct 2021.

PubMed  Article  Google Scholar 

Ehsan L, Waheed M, Akbar F, Siddiqui Z, Sattar A, Kirmani S. Challenges and opportunities in the establishment of a hereditary breast cancer clinic at an academic medical center in a low-middle income country. J Genet Couns. 2022; Available: https://onlinelibrary.wiley.com/doi/10.1002/jgc4.1555.

NCCN. National Comprehensive Cancer Network. Familial/Genetic, High-Risk Assessment, Breast, Ovarian and Pancreatic (Version:1.2016 ): National Comprehensive Cancer Network; 2016. Available from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.

Google Scholar 

Prevention Genetics. Hereditary Breast and Ovarian Cancer - Expanded and Lynch Syndrome Panel: PreventionGenetics. Available from: https://www.preventiongenetics.com/testInfo?val=Hereditary+Breast+and+Ovarian+Cancer+-+Expanded+and+Lynch+Syndrome+Panel. Cited 5 May 2021.

Invitae Genetics. Invitae breast and Gyn cancers panel: Invitae Genetics; 2021. Available at: https://www.invitae.com/en/physician/tests/01201/#info-panel-assay_information>. Accessed 5 May 2021.

Google Scholar 

Illumina. Illumina.com. 2021. Illumina | Sequencing and array-based solutions for genetic research. Available from: https://www.illumina.com/. Cited 5 May 2021.

Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–23. Available from: https://www.nature.com/articles/gim201530. Cited 6 Oct 2021.

PubMed  Article  PubMed Central  Google Scholar 

Kim DH, Chae H, Jo I, et al. Identification of large genomic rearrangement of BRCA1/2 in high risk patients in Korea. BMC Med Genet. 2017;18:38. https://doi.org/10.1186/s12881-017-0398-3.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kang E, Seong MW, Park SK, Lee JW, Lee J, Kim LS, et al. The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study. Breast Cancer Res Treat. 2015;151(1):157–68. https://doi.org/10.1007/s10549-015-3377-4. Epub 2015 Apr 12. PMID: 25863477.

CAS  Article  PubMed  Google Scholar 

Kwong A, Shin VY, Au CH, Law FBF, Ho DN, Ip BK, et al. Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. J Mol Diagnostics. 2016;18(4):580–94. https://doi.org/10.1016/j.jmoldx.2016.03.005. ISSN 1525-1578.

CAS  Article  Google Scholar 

San.gva.es. 2020. Available from: http://www.san.gva.es/documents/246911/251004/gpcHEREDITARIO.pdf>. Accessed 10 Dec 2020.

Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genetics. 2014;207(5):195–205. https://doi.org/10.1016/j.cancergen.2014.05.002.

CAS  Article  PubMed  Google Scholar